Endothelial dysfunction, impaired endogenous fibrinolysis, and cigarette smoking: A mechanism for arterial thrombosis and myocardial infarction

Circulation

Volumn 99, Issue 11, 1999, Pages 1411-1415

  Newby, David E ^a   Wright, Robert A ^a,b   Labinjoh, Catherine ^a   Ludlam, Christopher A ^a   Fox, Keith A A ^a   Boon, Nicholas A ^a   Webb, David J ^a  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

^b AYR HOSPITAL   (United Kingdom)

Author keywords

Blood flow; Endothelium; Endothelium derived factors; Plasminogen activators

Indexed keywords

PLASMINOGEN ACTIVATOR INHIBITOR 1; SUBSTANCE P; TISSUE PLASMINOGEN ACTIVATOR;

ADULT; AREA UNDER THE CURVE; ARTERY THROMBOSIS; ARTICLE; BRACHIAL ARTERY; CIGARETTE SMOKING; CONTROLLED STUDY; DOSE RESPONSE; ENDOTHELIUM INJURY; FEMALE; FIBRINOLYSIS; FOREARM BLOOD FLOW; HEART INFARCTION; HUMAN; HUMAN EXPERIMENT; INTRAARTERIAL DRUG ADMINISTRATION; MALE; NORMAL HUMAN; PRIORITY JOURNAL; RISK FACTOR;

EID: 0033596924     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.99.11.1411     Document Type: Article

References (46)

1. Burke AP, Farb A, Malcolm GT, Liang YH, Smialek J, Virmani R. Coronary risk factors and plaque morphology in men with coronary artery disease who died suddenly. N Engl J Med. 1997;336:1276-1282.
2. Davies MJ. The composition of coronary artery plaques. N Engl J Med. 1997;336:1312-1314.
3. Chen L, Chester M, Kaski JC. Clinical factors and angiographic features associated with premature coronary artery disease. Chest. 1995;108: 364-369.
4. Njolstad I, Arnesen E, Lund-Larsen PG. Smoking, serum lipids, blood pressure, and sex differences in myocardial infarction: a 12-year follow-up of the Finnmark study. Circulation. 1996;93:450-456.
5. Hung J, Lam JYT, Lacoste L, Letchacovski G. Cigarette smoking acutely increases platelet thrombus formation in patients with coronary artery disease taking aspirin. Circulation. 1995;92:2432-2436.
6. Celermajer DS, Adams MR, Clarkson P, Robinson J, McCredie R, Donald A, Deanfield JE. Passive smoking and impaired endothelium-dependent arterial dilatation in healthy young adults. N Engl J Med. 1996;334:150-154.
7. Davies MJ, Woolf N, Rowles PM, Pepper J. Morphology of the endothelium over atherosclerotic plaques in human coronary arteries. Br Heart J. 1988;60:459-464.
8. Bürrig KF. The endothelium of advanced arteriosclerotic plaques in humans. Arterioscler Thromb. 1991;11:1678-1689.
9. Armstrong PW, Baigrie RS, Dajy PA, Haq A, Gent M, Roberts RS, Freeman MR, Burns R, Liu P, Morgan CD. Tissue plasminogen activator: Toronto (TPAT) placebo-controlled randomized trial in acute myocardial infarction. J Am Coll Cardiol. 1989;13:1469-1476.
10. DeWood MA, Spores J, Notske R, Mouser LT, Burroughs R, Golden MS, Lang HT. Prevalence of total coronary artery occlusion during the early hours of transmural myocardial infarction. N Engl J Med. 1980;303: 897-902.
11. Rentrop KP, Feit F, Blanke H, Sherman W, Thornton JC. Serial angiographic assessment of coronary artery obstruction and collateral flow in acute myocardial infarction. Circulation. 1989;80:1166-1175.
12. Thompson SG, Kienast J, Pyke SDM, Haverkate F, van de Loo JCW, for the European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group. Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. N Engl J Med. 1995;332:635-641.
13. Hamsten A, Wiman B, de Faire U, Blombäck M. Increased plasma levels of a rapid inhibitor of tissue plasminogen activator in young survivors of myocardial infarction. N Engl J Med. 1985;313:1557-1563.
14. Ridker PM, Vaughan DE, Stampfer MJ, Manson JE, Hennekens CH. Endogenous tissue-type plasminogen activator and risk of myocardial infarction. Lancet. 1993;341:1165-1168.
15. Meade TW, Ruddock V, Stirling Y, Chakrabarti R, Miller GJ. Fibrinolytic activity, clotting factors, and long-term incidence of ischaemic heart disease in the Northwick Park Heart Study. Lancet. 1993;342:1076-1079.
16. Jansson JH, Olofsson BO, Nilsson TK. Predictive value of tissue plasminogen activator mass concentration on long-term mortality in patients with coronary artery disease. Circulation. 1993;88:2030-2034.
17. Jern C, Ladenwall P, Wall U, Jern S. Gene polymorphism associated with vascular release of tissue-type plasminogen activator (t-PA) in vivo. Eur Heart J. 1997;18:144. Abstract.
18. Newby DE, Wright RA, Ludlam CA, Fox KAA, Boon NA, Webb DJ. An in vivo model for the assessment of the acute fibrinolytic capacity of the endothelium. Thromb Haemost. 1997;78:1242-1248.
19. Newby DE, Wright RA, Dawson P, Ludlam CA, Fox KAA, Boon NA, Webb DJ. The L-arginine:nitric oxide pathway contributes to the acute release of tissue plasminogen activator in vivo in man. Cardiovasc Res. 1998;38:485-492.
20. Benjamin N, Calver A, Collier J, Robinson B, Vallance P, Webb D. Measuring forearm blood flow and interpreting the responses to drugs and mediators. Hypertension. 1995;25:918-923.
21. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972;18:499-502.
22. Bland JM, Altman DG. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet. 1986;1:307-310.
23. Fox KAA, Robison AK, Knabb RM, Rosamond TL, Sobel BE, Bergmann SR. Prevention of coronary thrombosis with subthrombolytic doses of tissue-type plasminogen activator. Circulation. 1984;72:1346-1354.
24. Brommer EJP. The level of extrinsic plasminogen activator (t-PA) during clotting as a determinant of the rate of fibrinolysis: inefficiency of activators added afterwards. Thromb Res. 1984;34:109-115.
25. Håheim LL, Holme I, Hjermann I, Leren P. The predictability of risk factors with respect to incidence and mortality of myocardial infarction and total mortality: a 12-year follow-up of the Oslo Study, Norway. J Intern Med. 1993;234:17-24.
26. Barbash GI, White HD, Modan M, Diaz R, Hampton JR, Heikkila J, Kristinsson A, Moulopoulos S, Paolasso EAC, Van der Werf T, Pehrsson K, Sandoe E, Simes J, Wilcox RG, Verstraete M, von der Lippe G, Van der Werf F, for the investigators of the International Tissue Plasminogen Activator/Streptokinase Mortality Trials. Significance of smoking in patients receiving thrombolytic therapy for acute myocardial infarction. Circulation. 1993;87:53-58.
27. Mueller HS, Cohen LS, Braunwald E, Forman S, Feit F, Ross A, Schweiger M, Cabin H, Davison R, Miller D, Solomon R, Knatterud GL, for the TIMI investigators. Predictors of early morbidity and mortality after thrombolytic therapy of acute myocardial infarction: analyses of patient subgroups in the Thrombolysis In Myocardial Infarction (TIMI) trial, phase II. Circulation 1992;85:1254-1264.
28. Zahger D, Cercek B, Cannon CP, Jordan M, Davis V, Braunwald E, Shah PK, for the TIMI-4 investigators. How do smokers differ from non-smokers in their response to thrombolysis? (The TIMI-4 trial). Am J Cardiol. 1995;75:232-236.
29. Gomez MA, Karagounis LA, Allen A, Anderson JL, for the TEAM-2 Investigators. Effect of cigarette smoking on coronary artery patency after thrombolytic therapy for acute myocardial infarction. Am J Cardiol. 1993;72:373-378.
30. de Chillou C, Riff P, Sadoul N, Éthevenot G, Feldmann L, Isaaz K, Simon J-P, Boursier M, Khalifé K, Thisse J-Y, Aliot E. Influence of cigarette smoking on rate of reopening of the infarct-related coronary artery after myocardial infarction: a multivariate analysis. J Am Coll Cardiol. 1996; 27:1662-1668.
31. Allen RA, Kluft C, Brommer EJP. Effect of chronic smoking on fibrinolysis. Arteriosclerosis. 1985;5:443-449.
32. Gris JC, Schved JF, Brun S, Brunschwig C, Petris I, Lassonery M, Martinez P, Sarlat C. Venous occlusion and chronic cigarette smoking: dose-dependent decrease in the measurable release of tissue-type plasminogen activator and von Willebrand factor. Atherosclerosis. 1991;91: 247-255.
33. Held C, Hjemdahl P, Rehnqvist N, Wallén H, Björkander I, Eriksson SV, Forslund L, Wiman B. Fibrinolytic variables and cardiovascular prognosis in patients with stable angina pectoris treated with verapamil or metoprolol. Circulation. 1997;95:2380-2386.
34. Jahun-Vague I, Pyke SDM, Alessi MC, Jespersen J, Haverkate F, Thompson SG, on behalf of the ECAT Study Group. Fibrinolytic factors and the risk of myocardial infarction or sudden cardiac death in patients with angina pectoris. Circulation. 1996;94:2057-2063.
35. Mannucci PM. Desmopressin (DDAVP) in the treatment of bleeding disorders: the first 20 years. Blood. 1997;90:2515-2521.
36. Gross DR, Fiscus RR, Arden WA, Maley RH, Lanzo S, Salley RK. Substance P induces biphasic endothelium-dependent relaxations in pig and rabbit carotid arteries. Neuropeptides. 1994;26:329-341.
37. Newby DE, Boon NA, Webb DJ. Comparison of forearm vasodilatation induced by substance P and acetylcholine: contribution of nitric oxide. Clin Sci. 1997;92:133-138.
38. Newby DE, Sciberras DG, Mendel CM, Gertz BJ, Boon NA, Webb DJ. Intra-arterial substance P mediated vasodilatation in the human forearm: pharmacology, reproducibility and tolerability. Br J Clin Pharmacol. 1997;43:493-499.
39. Heitzer T, Ylä-Herttuala S, Luoma J, Kurz S, Münzel T, Just H, Olschewski M, Drexler H. Cigarette smoking potentiates endothelial dysfunction of forearm resistance vessels in patients with hypercholesterolemia: role of oxidized LDL. Circulation. 1996;93:1346-1353.
40. Heitzer T, Just H, Münzel T. Antioxidant vitamin C improves endothelial dysfunction in chronic smokers. Circulation. 1996;94:6-9.
41. Hirooka Y, Egashira K, Imaizumi T, Tagawa T, Kai H, Sugimachi M, Takeshita A. Effects of L-arginine on acetylcholine-induced endothelium-dependent vasodilation differs between the coronary and forearm vasculatures in humans. J Am Coll Cardiol. 1994;24:948-955.
42. Sax FL, Cannon RO, Hanson C, Epstein SE. Impaired forearm vasodilator reserve in patients with microvascular angina: evidence of a generalized disorder of vascular function? N Engl J Med. 1987;317: 1366-1370.
43. Pedrinelli R, Spessot M, Chiriatti G, Gistri R, Salvadori P, Catapano G, Panarace G, Papi L, L'Abbate A, Camici PG. Evidence for a systemic defect of resistance-sized arterioles in hypertrophic cardiomyopathy. Coron Artery Dis. 1993;4:67-72.
44. Shennan NM, Seed M, Wynn V. Variation in serum lipid and lipoprotein levels associated with changes in smoking behaviour in non-obese Caucasian males. Atherosclerosis. 1985;58:17-25.
45. Ferrara A, Barrett-Connor E, Shan J. Total, LDL, and HDL cholesterol decrease with age in older men and women: the Rancho Bernardo study 1984-1994. Circulation. 1997;96:37-43.
46. Koh KK, Mincemoyer R, Bui MN, Csako G, Pucino F, Guetta V, Waclawiw M, Cannon RO. Effects of hormone-replacement therapy on fibrinolysis in postmenopausal women. N Engl J Med. 1997;336: 683-690.